Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of care/Placebo Clear all
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02545504
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Andecaliximab, Placebo, Leucovorin, 5-fluorouracil, Oxaliplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
31
States / cities
La Jolla, California • Los Angeles, California • Whittier, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D3 for Aromatase Inhibitor Induced Arthralgias

NCT00867217
View directory record Official record
Conditions
Breast Cancer
Interventions
High Dose Vitamin D, Placebo, Standard Dose Vitamin D3, Letrozole 2.5mg
Dietary Supplement · Drug
Lead sponsor
Qamar Khan
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Westwood, Kansas • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT03782376
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab approximately 6 mg/kg (IV), Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 4, 2026, 11:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

NCT00958776
View directory record Official record
Conditions
Cough, Sore Throat, Nasal Congestion, Headache, Fever, Seasonal Influenza
Interventions
Peramivir+SOC, Placebo+SOC
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
60
States / cities
La Mesa, California • Long Beach, California • Modesto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 4, 2026, 11:15 AM EDT
Terminated Phase 1Phase 2 Interventional

Use of Oxandrolone to Promote Growth in Infants With HLHS

NCT04090697
View directory record Official record
Conditions
Hypoplastic Left Heart, Congenital Heart Disease
Interventions
Oxandrolone
Drug
Lead sponsor
Carelon Research
Other
Eligibility
Up to 14 Days
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

NCT01720446
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
3,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
97
States / cities
Birmingham, Alabama • Chandler, Arizona • Anaheim, California + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 4, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 4, 2026, 11:15 AM EDT
Not listed Phase 3 Interventional

Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery

NCT01500369
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
sphygmomanometer cuff inflations, standard of care
Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 4, 2026, 11:15 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 4, 2026, 11:15 AM EDT
Not listed Phase 1Phase 2 Interventional

Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO

NCT02851472
View directory record Official record
Conditions
Anemia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
New York Medical College
Other
Eligibility
2 Weeks and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Springfield, Massachusetts • Stony Brook, New York • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Not applicable Interventional

Motor Learning Approach for Manual Wheelchair Users

NCT03781609
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Roller system group (RG), Overground group (OG), Placebo - Wheelchair skills group (WSG)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 4, 2026, 11:15 AM EDT
Enrolling by invitation Phase 4 Interventional

Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome

NCT06306157
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Chronic Pain, Causalgia, Complex Regional Pain Syndrome Type I, Complex Regional Pain Syndrome Type II
Interventions
Low dose naltrexone, Placebo sugar capsules
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 4, 2026, 11:15 AM EDT
Terminated Phase 3 Interventional Results available

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

NCT00385138
View directory record Official record
Conditions
Atherosclerosis, Acute Coronary Syndrome (ACS)
Interventions
Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
5,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Results available

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

NCT02465515
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Albiglutide 30 mg, Albiglutide 50 mg, Albiglutide matching placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
9,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
146
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

NCT00158743
View directory record Official record
Conditions
Pre-eclampsia
Interventions
Anti-digoxin antibody (FAB fragment), sodium chloride
Drug · Other
Lead sponsor
BTG International Inc.
Other
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

NCT00078013
View directory record Official record
Conditions
Myocardial Infarction
Interventions
MCC-135
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140
View directory record Official record
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 4, 2026, 11:15 AM EDT
Terminated Phase 3 Interventional

Erector Spinae Plane Block With Bupivacaine for Medical Thoracoscopy

NCT06313632
View directory record Official record
Conditions
Pleural Disease, Postoperative Pain
Interventions
Bupivacaine injection, Placebo, Monitored Anesthesia Care
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01510158
View directory record Official record
Conditions
Gout
Interventions
Lesinurad, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
165
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 139 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 4, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Opioid Analgesia for MAB

NCT03139240
View directory record Official record
Conditions
MAB, Pain
Interventions
Oxycodone 10mg oral, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Beaverton, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 4, 2026, 11:15 AM EDT
Not yet recruiting Phase 2 Interventional

HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

NCT07760948
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
Interventions
Calcium-HMB Plus Vitamin D3, Matching placebo
Dietary Supplement · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
65 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 4, 2026, 11:15 AM EDT
Recruiting Not applicable Interventional

Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)

NCT07241585
View directory record Official record
Conditions
Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
Interventions
Vitamin D (VitD), Placebo, Photodynamic therapy (PDT), Mohs surgery or electrodessication & curettage (ED&C) (standard of care)
Dietary Supplement · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 4, 2026, 11:15 AM EDT